Teva Pharmaceutical Industries Limited Ordinary Shares (NY:TEVA)

39.53 +0.22 (+0.56%)

Official Closing Price Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries Limited Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

35 36 Next >

How Is The Market Feeling About Teva Pharmaceutical Indus? ↗

August 18, 2025

Via Benzinga

FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine

August 06, 2025

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Teva Pharma Boosts Outlook For Key Innovative Drugs Austedo, Ajovy, Uzedy ↗

July 30, 2025

Teva raised 2025 guidance for Austedo, Ajovy, and Uzedy after Q2 earnings beat estimates, despite missing revenue expectations.

Via Benzinga

Topics Earnings

Why Drugmaker Teva Pharmaceutical Narrowed Full-Year Guidance After Beating Q2 Earnings ↗

July 30, 2025

Teva stock is trading below key levels.

Via Investor's Business Daily

Earnings Scheduled For July 30, 2025 ↗

July 30, 2025

Via Benzinga

How Do Investors Really Feel About Teva Pharmaceutical Indus? ↗

June 05, 2025

Via Benzinga

Where Teva Pharmaceutical Indus Stands With Analysts ↗

May 28, 2025

Via Benzinga

Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components

July 30, 2025

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Generic Revlimid Fades, But Teva's Broader Generics Outlook Remains Strong ↗

July 29, 2025

Teva anticipates EBITDA recovery post-2025 as Austedo and Uzedy grow and generic Revlimid faces rising competition.

Via Benzinga

A Glimpse of Teva Pharmaceutical Indus's Earnings Potential ↗

July 29, 2025

Via Benzinga

Billionaire Stanley Druckenmiller Sold His Entire Stake in Palantir and Has Loaded Up on These 2 Exceptional Stocks for 3 Consecutive Quarters ↗

July 18, 2025

Duquesne Family Office's billionaire chief dumped his fund's stake in Wall Street's artificial intelligence (AI) darling in favor of two reasonably cheap stocks that have taken off in recent years.

Via The Motley Fool

Topics Artificial Intelligence

10 Health Care Stocks Whale Activity In Today's Session ↗

July 15, 2025

Via Benzinga

Looking Into Teva Pharmaceutical Indus's Recent Short Interest ↗

July 10, 2025

Via Benzinga

Teva Releases Q2 2025 Aide Memoire

June 26, 2025

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

What Analysts Are Saying About Teva Pharmaceutical Indus Stock ↗

June 26, 2025

Via Benzinga

The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough

June 26, 2025

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:TEVA),(NASDAQ:CTOR),(NYSE:ADCT),(NYSE:OSTX) EQNX::TICKER_END

Via FinancialNewsMedia

Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025

June 25, 2025

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Billionaire Stanley Druckenmiller Loaded Up on These 3 Stocks. Are They Buys? ↗

June 25, 2025

Via The Motley Fool

Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology

June 16, 2025

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030

June 18, 2025

EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:NTRBW),(NYSE:PFE),(NASDAQ:COLL),(NYSE:TEVA),(NYSE:EBS) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Death

Billionaire Stanley Druckenmiller Dumped His Entire Stake in Palantir and Has Piled Into This Suddenly Unstoppable Drug Stock for 3 Straight Quarters ↗

June 16, 2025

Duquesne Family Office's billionaire chief sold every share of Wall Street's hottest artificial intelligence (AI) stock in favor of a drugmaker whose shares have surged 142% in two years.

Via The Motley Fool

Topics Artificial Intelligence Economy

Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030

June 18, 2025

From FN Media Group LLC

Via GlobeNewswire

Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris? ↗

June 06, 2025

Goldman Sachs initiates Teva, Viatris, and Amneal, highlighting branded growth and pipeline strength, but one company's unclear outlook.

Via Benzinga

9 Health Care Stocks Whale Activity In Today's Session ↗

June 04, 2025

Via Benzinga

Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer

June 03, 2025

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement

June 03, 2025

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025

May 30, 2025

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with

May 30, 2025

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Teva Reaffirms Growth Strategy, Eyes $5 Billion Innovative Franchise By 2030 ↗

May 29, 2025

Teva outlines its accelerated growth strategy focused on innovation, aiming for $5 billion in biopharma revenue by 2030, while maintaining a strong generics and biosimilars base.

Via Benzinga

Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day

May 29, 2025

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

35 36 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.